[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
Whether the sensorylikingwanting dissociation proposed for GLP-1RAs is maintained, strengthened, or modified under dual, triple-agonist and amylin-based co-agonist therapy remains uncertain
Suboptimal dosing : Patients may be on a dose intended for diabetes management (0.5-1.0 mg weekly) rather than the higher dose approved for weight loss (2.4 mg weekly)
(287) performed a secondary analysis of the CORDIOPREV study, including 1,002 patients with coronary heart disease randomized to either a Mediterranean diet or low-fat diet group with 7-year follow-up
Nothing on this page should be interpreted as a recommendation, instruction, or endorsement for personal use